Browsing by Author "Demir, C"

Now showing 1 - 4 of 4

Ca 125 Levels in Patients With Non-Hodgkin Lymphoma and Other Hematologic Malignancies
(Wiley, 2005) Dilek, I; Ayakta, H; Demir, C; Meral, C; Ozturk, M
Cancer antigen (CA 125) is a glycoprotein commonly used as a tumor marker. In this study, CA 125 levels were measured in 149 patients and 26 healthy control subjects. The study group included 69 non-Hodgkin lymphomas (NHL), 25 Hodgkin disease (HD), 20 acute myelocytic leukemia (AML), 14 chronic lymphocytic leukemia (CLL), 12 chronic myelocytic leukemia (CML), and nine multiple myeloma (MM) patients. CA 125 was elevated in 37 of the patients and in none of the control subjects. Average CA 125 level in NHL patients was significantly higher than the controls (56.2+/-9.2 U/ml, 7.99+/-1.05 U/ml respectively) (P<0.05). CA 125 levels were significantly higher in NHL patients with abdominal involvement (113.6+/-23.4 U/ml), with B-symptoms (72.3+/-13.2 U/ml), higher stage of the disease (stages III and IV -75.3+/-14.9 U/ml), bulky disease (99.9+/-30.4 U/ml) and in those with serosal involvement (103.1+/-18.5 U/ml) (P<0.05 for all). CA 125 levels were also elevated in seven patients with HD and in a patient with CLL with pleural effusion. In conclusion, for patients with NHL, high levels of CA 125 were associated with B-symptoms, advanced stage, bulky disease, abdominal, and serosal involvement. Therefore, CA 125 might be used as a marker to predict prognosis and to detect advanced disease in NHL.
Effect of Hormone Replacement Therapy on Cd4+ and Cd8+ Numbers, Cd4+ Ratio, and Immunoglobulin Levels in Hemodialysis Patients
(Taylor & Francis Ltd, 2005) Dogan, E; Erkoc, R; Demir, C; Sayarlioglu, H; Dilek, I; Sayarlioglu, M
Uremia induces a suppression of the immune status. A large clinical literature suggests that estradiol (E-2) plays a critical role in immune function. A large proportion of women hemodialysis patients faced early menopause and inadequate estrogen levels. The aim of the present study is to evaluate the effect of hormone replacement therapy on immune function in terms of CD4(+) numbers (inducer/helper T cells), CD8(+) numbers (cytotoxic/ suppressor T cells), CD4(+)/CD8(+) ratio, and IgG, IgM, IgA levels in woman hemodialysis patients. In our study, 15 female hemodialysis patients (median age 32.6 range 24-45) were treated with triphasic estrogen/progesterone preparation (estradiol 2 mg for 10 days, and afterwards estradiol 2 mg+norethisterone 1 mg for another 10 days, and at the end estradiol 1 mg for 6 days) for 6 months. CD4(+) numbers, CD8(+) numbers, and IgG, IgA, and IgM levels were determined before and after HRT. The "paired-samples T" test was used for statistical analysis of pretreatment and posttreatment values. A significant increase was observed for CD4(+) numbers (582 +/- 435 versus 637 +/- 445, p=0.04) and CD4(+)/CD8(+) ratio (1.4 +/- 0.16 to 2.4 +/- 0.3, p<0.01) after hormone replacement therapy (HRT). Serum immunoglobulin levels were not changed significantly. In conclusion, in postmenopausal hemodialysis patients, HRT significantly increased CD4(+) numbers and CD4(+)/CD8(+) ratio, but no effect was observed in IgM, IgG, and IgA levels. Long-term clinical effects of HRT on immune system should be investigated in dialysis patients with further studies.
Hematological Malignancy and Pregnancy
(Blackwell Publishing, 2006) Dilek, I; Topcu, N; Demir, C; Bay, A; Uzun, K; Gul, A; Ugras, S
The incidence of hematological malignancies during pregnancy is low, and treatment in this setting is problematic. This study observed 21 pregnancies in 18 patients with hematological malignancies. Patients' ages were between 19 and 43 (median 25) years. Two pregnancies ended with spontaneous abortion, one pregnancy ended with in utero death, three therapeutic abortions were carried out, and 15 infants were born alive but three of them died later. The median birth weight was 2.47 kg. Twelve babies survived to a median age of 36 (range 4-117) months. Eight babies were exposed to chemotherapy during the in utero period. One baby was exposed to chemotherapy during all the trimesters and was born prematurely and later died because of intracranial bleeding. Four babies were exposed to chemotherapy during the first trimester, one of them had low birth weight and floating thumb malformation, two of them had only low birth weight, and one was born healthy, but died at 3 months of age as a result of severe gastroenteritis. Two babies were exposed to chemotherapy during the second and third trimesters; one of them had low birth weight, and the other pregnancy ended in in utero death. One infant was exposed to chemotherapy during the third trimester and was born at term, but died because of pulmonary hemorrhage. We concluded that chemotherapy during all trimesters of pregnancy carries a significant risk for an unfavorable outcome.
Microalbuminuria in Hodgkin's Disease
(Wiley, 2005) Dilek, I; Demir, C; Üstün, Y; Erkoç, R
In some malignant disorders, it was reported that urinary albumin excretion (UAE) was correlated with the prognosis and the extent of the disease. In this study, 24-h UAE was determined in 34 Hodgkin's disease patients without prior treatment and 19 healthy controls. Microalbuminuria (MAU) was defined as UAE >= 20 mu g/min. In patients with MAU, UAE was determined again after the treatment. Mean UAE was 31.2 mu g/min in the patient group and 5.6 mu g/min in the controls (p = 0.005). Whereas MAU frequency was 47% in the patients, there was no MAU in the controls. Mean UAE tended to be higher in advanced stage patients compared to early stage patients (p = 0.051). Also, MAU frequency tended to be higher in the advanced stage group compared to the early stage group (p = 0.196). In four patients in whom remission could not have been achieved, although UAE was reduced, MAU did not disappear. In conclusion, UAE was increased in Hodgkin's disease. However, there is no significant correlation between UAE and the disease extent.